Parliamentary Search

Written question asked by Lee Anderson (Reform UK) on Monday, 15 June 2026, in the House of Commons. It was due for an answer on Wednesday, 17 June 2026. It was answered by Preet Kaur Gill (Labour) on Monday, 29 June 2026 on behalf of the Department of Health and Social Care.

Fezolinetant

Question

To ask the Secretary of State for Health and Social Care, what discussions he has had with healthcare professionals on the suitability of prescribing fezolinetant for routine use.

Answer

Fezolinetant is a non-hormonal medicine used to treat moderate to severe hot flushes and night sweats linked to menopause. It may be used where hormone replacement therapy is not suitable.

The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating these symptoms when hormone replacement therapy is unsuitable. NICE is the independent body that assesses whether medicines should be routinely funded by the National Health Service, based on clinical and cost effectiveness. Once NICE recommends a medicine, the NHS in England is normally legally required to fund it within three months of the final guidance. Integrated care boards are therefore expected to make fezolinetant available in line with NICE’s recommendation. Decisions about whether it is right for an individual patient remain for clinicians to make with their patients.

Secondary information

Type
Written question
Reference
9676
Session
2026-27
Grouped for answer
Yes
Subjects
Menopause Fezolinetant
Link
View this Written question on www.parliament.uk